News - Bristol-Myers Squibb


Current filters:

Bristol-Myers Squibb

Popular Filters

120 to 144 of 222 results

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments


The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Bristol-Myers goes into red, on charges and Plavix sales slump


US drug major Bristol-Myers Squibb (NYSE: BMY) reported financial results for the third quarter of 2012,…

Bristol-Myers SquibbFinancialPharmaceutical

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021


The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Top executive appointments at Boehringer and Bristol-Myers


German family-owned drug major Boehringer Ingelheim says that Engelbert Tjeenk Willink, a member of the…

Boehringer IngelheimBristol-Myers SquibbManagementPharmaceutical

FDA sets March 2013 PDUFA date for re-submitted Eliquis


The US Food and Drug Administration has acknowledged receipt of the New Drug Application resubmission…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Bristol-Myers links with Vanderbilt for Parkinson's research


US drug major Bristol-Myers Squibb (NYSE: BMY) has signed up for a collaboration with Vanderbilt University…

Bristol-Myers SquibbNeurologicalPharmaceuticalResearch

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report


The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Decline in cardiovascular drugs noted at ESC congress


This year's European Society of Cardiology (ESC) Congress in Munich, Germany, was a stark example of…

apixabanBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingPfizerPharmaceuticalResearch

Summit licenses Seglin technology to Bristol-Myers


UK drug discovery firm Summit Pharmaceuticals (AIM: SUMM) has entered a technology license agreement…

Bristol-Myers SquibbLicensingPharmaceuticalResearchSummit Pharmaceuticals

Teva launches generic Aprovel in UK


The UK subsidiary of Israel's Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic…

AprovelBristol-Myers SquibbCardio-vascularEuropeGenericsMarkets & MarketingSanofiTeva Pharmaceutical Industries

Synergy Pharma gains rights to shingles drug from Bristol-Myers


US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Anti-clotting drugs prasugrel and clopidogrel yield similar results


The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Bristol-Myers drops hep C pill on patient safety issues


US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe


In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Pharma partnering dollars continue to decline, Burrill & Co reports


The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ


US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

Patent expiries batter Bristol-Myers 2nd-quarter 2012 results


Bristol-Myers Squibb (NYSE: BMY) posted second quarter 2012, highlighted by the planned $5.3 billion…

Bristol-Myers SquibbFinancialPharmaceutical

Bristol-Myers brivanib fails in Ph III liver cancer trial


US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

120 to 144 of 222 results

Company Spotlight



Back to top